Premium
Consensus statement urges caution in using ketamine for treating depression
Publication year - 2017
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30233
Subject(s) - statement (logic) , ketamine , depression (economics) , citation , mood , task force , psychopharmacology , medicine , psychiatry , psychology , computer science , library science , political science , law , public administration , economics , macroeconomics
With ketamine infusion therapy generating significant interest for the treatment of mood disorders despite a lack of evidence from large‐scale trials, a subgroup of an American Psychiatric Association (APA) task force has issued a consensus statement on critical issues to consider in this off‐label use of ketamine. Among the statement's recommendations are that the number of ketamine treatments should be limited to the minimum necessary to achieve response and that providers should assess for the patient's potential to develop a ketamine use disorder.